```

[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[S. 3478 Introduced in Senate (IS)]

<DOC>

117th CONGRESS
  2d Session
                                S. 3478

  To provide for the designation of biological products as qualified 
                      infectious disease products.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

             January 11 (legislative day, January 10), 2022

  Mr. Casey (for himself, Mr. Cassidy, and Mr. Murphy) introduced the 
 following bill; which was read twice and referred to the Committee on 
                 Health, Education, Labor, and Pensions

_______________________________________________________________________

                                 A BILL

 
  To provide for the designation of biological products as qualified 
                      infectious disease products.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Generating Antibiotic Incentives Now 
Through Opening Opportunities to Leverage Science Act of 2022'' or the 
``GAIN TOOLS Act of 2022''.

SEC. 2. EXPANDING QUALIFIED INFECTIOUS DISEASE PRODUCTS TO INCLUDE 
              BIOLOGICAL PRODUCTS.

    (a) In General.--Section 505E of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 355f) is amended--
            (1) in subsection (c)--
                    (A) in paragraph (2), by striking ``; or'' and 
                inserting ``;'';
                    (B) in paragraph (3), by striking the period and 
                inserting ``; or''; and
                    (C) by adding at the end the following:
            ``(4) an application pursuant to section 351(a) of the 
        Public Health Service Act.'';
            (2) in subsection (d)(1), by inserting ``of this Act or 
        section 351(a) of the Public Health Service Act'' after 
        ``section 505(b)''; and
            (3) by amending subsection (g) to read as follows:
    ``(g) Qualified Infectious Disease Product.--The term `qualified 
infectious disease product' means a drug or biological product for 
human use that--
            ``(1) is--
                    ``(A) an antibacterial or antifungal drug; or
                    ``(B) a biological product that acts directly on 
                bacteria or fungi or on substances produced by such 
                bacteria or fungi; and
            ``(2) is intended to treat a serious or life-threatening 
        infection, including such an infection caused by--
                    ``(A) an antibacterial or antifungal resistant 
                pathogen, including novel or emerging infectious 
                pathogens; or
                    ``(B) qualifying pathogens listed by the Secretary 
                under subsection (f).''.
    (b) Priority Review.--Section 524A(a) of the Federal Food, Drug, 
and Cosmetic Act (21 U.S.C. 360n-1(a)) is amended by inserting ``of 
this Act, or section 351(a) of the Public Health Service Act, that 
requires clinical data (other than bioavailability studies) to 
demonstrate safety or effectiveness'' before the period.
                                 <all>
```